DEFINIUM THERAPEUTICS INC

DFTXNASDAQ

🏆 #923 by market capEarnings Nov 4US Equity

$40.91▼ $3.84 (−9.39%)

Live

1h—

24h▼ 9.4%

7d▼ 7.8%

14d▼ 2.9%

30d▼ 6.3%

1y▲ 303.5%

🏦Market Cap

$5.10B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $40.32 – $41.71
52-Week Range: $8.70 – $49.70
Volume: $2.51B
Avg Volume: $2.37B
Shares Outstanding: 124.6M
Next Earnings: Oct 29, 2026

Fundamentals Snapshot

Annual Revenue: $455M
Last Q Revenue: $112M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-3.43
Dividend Yield: —

Why Investors Own DFTX

✓High-growth profile — revenue up +56.0% YoY with expanding US Equity exposure.
✓Healthy economics — 58% gross margin and 12% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$455M▲ +50.2% YoY

Gross Margin (TTM)

57.5%▲ +1.6% YoY

Operating Income (TTM)

$155M▲ +50.2% YoY

Free Cash Flow (TTM)

$55M▲ +50.2% YoY

About DEFINIUM THERAPEUTICS INC

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

🦦